A Randomized, Global Study of Resolute Onyx Drug-Eluting Stent and One-Month Dual Antiplatelet Therapy

Trial Profile

A Randomized, Global Study of Resolute Onyx Drug-Eluting Stent and One-Month Dual Antiplatelet Therapy

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Zotarolimus (Primary) ; Aspirin
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Aug 2017 New trial record
    • 14 Aug 2017 According to a Medtronic media release, Stephan Windecker, M.D., of Bern University Hospital in Switzerland is the principal investigator of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top